众生药业：RAY0221是一款具有三靶点活性的多肽药物

Core Viewpoint - Zhongsheng Pharmaceutical's RAY0221 is a self-developed peptide drug targeting GLP-1, GIP, and GCG, aimed at treating diabetes, obesity, and non-alcoholic fatty liver disease, currently in the preclinical research stage [1] Group 1 - RAY0221 is designed to have multi-target activity, specifically focusing on GLP-1, GIP, and GCG [1] - The drug is intended for clinical applications in diabetes treatment, weight loss, and non-alcoholic fatty liver disease [1] - The project is currently in the preclinical research phase, with plans for orderly advancement in development [1]